← All trials
NCT06029530
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Aug 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Sep 8, 2023
- Last posted
- Nov 1, 2023
- Enrollment
- 70
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ohio State UniversityLead sponsor
- Case Western Reserve UniversityCollaborator
- Illinois College of OptometryCollaborator
- Indiana UniversityCollaborator
- Ohio State UniversityReponsible party - principal investigator
- Ohio State UniversityStudy chair
- Southern California College of Optometry at Marshall B. Ketchum UniversityCollaborator
- University of Alabama, BirminghamCollaborator
- Stanford UniversityCollaborator
- University of California, BerkeleyCollaborator
- University of HoustonCollaborator
- University of MissouriCollaborator
- University of the Incarnate WordCollaborator
- State University of New YorkCollaborator
- Ohio State UniversityOfficial
- Ohio State UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.